Thursday, February 13, 2020
2:30 to 4:30 pm
Milan at the Fondazione Telethon (Via Carlo Poerio, 14)
Research and innovation are the fundamental basis for guaranteeing growth in the life sciences sector and for allowing countries to take on the increasing challenges in the healthcare field. But this will require significant effort on an academic, scientific, industrial and, as a result, financial level.
In fact, one of the critical success factors in the life sciences sector is directly correlated to the financial resources made available for research and innovation and, above all, how these are allocated and managed.
The first meeting in 2020 of the Life Sciences Community returned to one of the cornerstones of the Community’s activity, and one that is of strategic importance for the growth and competitiveness of the life sciences sector: access to funding for research and innovation.
2020 will see, in fact, new programming in Europe for funds available to companies and other entities to invest in research and innovation and, specifically, Horizon Europe will have funding totaling approximately €100 billion over a 7-year period.
We talked about this with Giorgio Clarotti (Senior Policy Officer for Health, European Commission Research & Innovation Department), Francesca Pasinelli (Managing Director, Fondazione Telethon), Caterina Buonocore (Life Sciences Manager, APRE – Agency for the Promotion of European Research), Adriana Maggi (Professor of Pharmacology and Director of the Center for Pharmacological Biotechnologies, University of Milan), Vera Scuderi (Project Coordinator Community Life Sciences, The European House – Ambrosetti).
For information and to confirm attendance: email@example.com;
T. +39 02 46753.373